PDCD1 and neoplasm: Our pharmacokinetics study found that the average concentrations of PCC0208025 in plasma and tumor, at 1h, 3h and 8h after B16-F10 tumor-bearing mice were administrated with 60 mg/kg of PCC0208025, were similar to the IC50 values of PCC0208025 blockade against PD-1 and PD-L1 binding.